Poliovirus Tumor Vaccine for Breast Cancer Micro-Metastases.
Abstract
The underlying reason for failure to cure patients diagnosed with breast cancer is the presence of micrometastases. The stimulation of anti-tumor immune responses represents one of the most effective ways to treat low tumor burdens that are clinically occult. The objective of our proposal is to determine whether a poliovims replicon vaccine strategy induces systemic immunity and eradication of micrometastases. During the second year of our project, we have characterized poliovims replicons which express CEA or HER2/neu. Mice given these replicons generate anti-CEA or HER2/neu antibodies. We have demonstrated protection from tumor challenge in the mice which have antibodies to CEA. The significance of these studies is that we have now characterized the appropriate replicons that will be used to establish route of administration for generating an immune response against CEA or HER2/neu prior to tumor challenge. We are developing companion replicons which express biologically active immune modulators (OMCSF and IL-2) to increase the immunogenicity of the replicons encoding CEA or HER2/neu. The results of these studies will provide essential preclinical observations that will be relevant to the starting of human breast cancer trials targeted against cells that express CEA or HER2/neu.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1997
- Accession Number
- ADA334117
Entities
People
- Casey D. Morrow
Organizations
- University of Alabama